NIHR, Oxford Nanopore announce new health study

31 March 2023

Oxford Nanopore Technologies plc announces new human health and disease study led by the UK National Institute for Health and Care Research (NIHR) BioResource

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of Nanopore-based molecular sensing technology, today announces its participation in a cohort study led by the UK National Institute for Health and Care Research (NIHR) BioResource to further explore human health and disease.

The study would involve using Oxford Nanopore's platform to sequence up to 22,000 samples to further research in the initial areas of psychiatric, common and rare disease. Data would be made available to the scientific community through a managed access database hosted by the European Genome-phenome Archive (EGA) upon completion.

The NIHR BioResource is part of the NIHR and hosted by Cambridge University Hospitals NHS Foundation Trust (CUH) in partnership with the University of Cambridge and aligns with the UK government's strategy to extend the UK's leadership in genomic healthcare and research. This study will operate through a partnership between CUH and the University of Cambridge, with an additional partnership with King's College London.

Researchers will use Oxford Nanopore's high-throughput sequencing devices, the PromethION 48, which are uniquely designed to rapidly sequence large numbers of samples with high accuracy, delivering scalability for large projects.

The study is expected to start this year and complete in 2025.

[ENDS]

For further information, please contact:

Oxford Nanopore Technologies plc

Investors: ir@nanoporetech.com

Media: media@nanoporetech.com

Teneo (communications adviser to the Company)

Tom Murray, Olivia Peters, Lisa Jarrett-Kerr

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 120 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.

For more information please visit: www.nanoporetech.com

Forward-looking statements

This announcement contains certain forward-looking statements. For example, statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as "aim", "plan", "expect", "intend", "anticipate", "believe", "estimate", "target", and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition, and by definition address matters that are, to different degrees, uncertain. Our results could be affected by macroeconomic conditions, the COVID-19 pandemic, delays in our receipt of components or our delivery of products to our customers, suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen surveillance. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU no. 596/2014), which forms part of English law by virtue of the European Union (Withdrawal) Act 2018. The person responsible for arranging the release of this announcement on behalf of the Company is Hannah Coote, Company Secretary of Oxford Nanopore Technologies plc.

Read other news articles

Get In Touch

News